Increased overall morbidity in women with endometriosis: a population-based follow-up study until age 50

Rossi, Henna‐Riikka; Uimari, Outi; Anna, Terho; Paula, Pesonen; Koivurova, Sari; Terhi, Piltonen

doi:10.1016/j.fertnstert.2022.09.361

Cited by 8 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical symptoms include chronic pelvic pain, dysmenorrhea, and infertility (4). Endometriosis may increase a woman's risk for chronic diseases such as cancer or autoimmune disorders and overall morbidity as well (5)(6)(7). Endometriotic lesions can occur at different locations, including the pelvic peritoneum and the ovary, or infiltrate pelvic structures below the peritoneal surface (deep endometriosis).…”

Section: Article Length Targetmentioning

confidence: 99%

Development and Validation of a novelin vitrodiagnostic test for endometriosis

Herranz-Blanco¹,

Daoud²,

Viganò

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: To develop a non-invasive diagnostic test for endometriosis. Design: We conducted two studies: the development study (study 1) aimed at (i) evaluating the ability of CA125, brain-derived neurotrophic factor (BDNF) and clinical variables in segregating between cases and controls and (ii) developing a diagnostic algorithm based on those results. In the validation study (study 2), the clinical performance of the developed in vitro diagnostic (IVD) test, in diagnosing endometriosis was validated. Interventions: Serum samples and clinical variables extracted from psychometric questionnaires were collected from the Oxford Endometriosis CaRe Centre biobank (UK). Case/control classification was performed based on laparoscopy and histological verification of endometrial glands and/or stroma in the excised lesions. Main outcome measures: Study 1 and 2 included n=204 and n=79 patients, respectively. CA125 and BDNF concentrations were determined using the endometriosis IVD ELISA kit. In study 2, serum CA125 and BDNF concentrations and clinical variables were introduced into the IVD test software hosting the data treatment algorithm, which generates the qualitative diagnostic result (positive or negative). Results: Results from study 1 showed that, for both biomarkers levels, a statistically significant difference was found between cases and controls. Among all clinical variables related to patients medical history considered, six were significantly different between cases and controls: record of a previous surgery to investigate endometriosis presence, painful periods leading to referral for endometriosis presence, severity of menstrual pain during last cycle, age at first experience of intercourse pain, age at first regular use of painkillers and age at first diagnosis of ovarian cyst. In study 2, the novel endometriosis IVD test demonstrated sensitivity and specificity values of 46.2% (25.5-66.8%) and 100% (86.7-100%), respectively. Conclusion: BDNF and CA125, together with patient clinical variables, allowed efficient segregation between controls and endometriosis cases. Due to its high specificity, the novel endometriosis IVD test is an accurate rule-in non-invasive method, potentially contributing to diagnose endometriosis.

show abstract

Section: Article Length Targetmentioning

confidence: 99%

Development and Validation of a novelin vitrodiagnostic test for endometriosis

Herranz-Blanco¹,

Daoud²,

Viganò

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Clinical symptoms include but are not limited to chronic pelvic pain, dysmenorrhea, dyschezia, dysuria, and infertility [4]. Endometriosis may increase a woman's risk for chronic diseases such as cancer or autoimmune disorders, as well as overall morbidity [5][6][7]. Endometriotic lesions can occur in variable locations (both in and outside the pelvis), including the pelvic peritoneum and the ovary, and can infiltrate pelvic structures below the peritoneal surface (deep endometriosis).…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of an Endometriosis Diagnostic Method Based on Serum Biomarkers and Clinical Variables

et al. 2023

View full text Add to dashboard Cite

Endometriosis affects more than 10% of women of reproductive age, significantly impacting their quality of life. Diagnosis typically takes 4 to 11 years from symptom onset. The gold standard for diagnosing this disease, laparoscopy, is invasive, contributing to this delay in diagnosis. Two studies were conducted to develop a diagnostic test based on the combination of serum biomarkers and clinical variables. Study 1, the development study, aimed to: (i) confirm the ability of CA125, BDNF and clinical variables to differentiate between cases and controls, and (ii) develop a diagnostic algorithm based on these results. Study 2 validated the clinical performance of the developed in vitro diagnostic (IVD) test in diagnosing endometriosis. Serum samples and clinical variables extracted from psychometric questionnaires were obtained from the Oxford Endometriosis CaRe Centre biobank (UK). Case/control classification was performed based on laparoscopy and histological verification of the excised lesions. Studies 1 and 2 included n = 204 and n = 79 patients, respectively. Study 1 found a statistically significant difference between cases and controls for levels of both biomarkers. Of the assessed clinical variables from the patients’ medical histories, six were found to be significantly different between endometriosis cases and controls. CA125, BDNF and these six clinical variables were combined into a multivariable prediction model. In Study 2, the IVD test demonstrated sensitivity and specificity values of 46.2% (25.5–66.8%) and 100% (86.7–100%), respectively. Due to its high specificity, this IVD test is a simple and accurate rule-in test for early disease identification, even in the presence of non-specific symptoms.

show abstract

“…[23][24][25][26][27] In fact, most people are diagnosed with endometriosis after the age of 30. 28 To address the need for diagnosis of endometriosis among young adults, we must first understand the experiences of people with endometriosis and determine how people of different ages perceive the care they receive. [29][30][31][32] The objective of this study was to examine how people with endometriosis in different age groups experience the endometriosis diagnostic process.…”

Section: Introductionmentioning

confidence: 99%

“…Although endometriosis has been identified by laparoscopy in up to 70% of adolescents presenting with female chronic pelvic pain, laparoscopic diagnosis of endometriosis is typically delayed until adulthood 23–27 . In fact, most people are diagnosed with endometriosis after the age of 30 28 . To address the need for diagnosis of endometriosis among young adults, we must first understand the experiences of people with endometriosis and determine how people of different ages perceive the care they receive 29–32 …”

Section: Introductionmentioning

confidence: 99%

Patient experiences of endometriosis diagnosis: A mixed methods approach

Requadt,

Nahlik,

Jacobsen

et al. 2023

BJOG

View full text Add to dashboard Cite

ObjectiveTo examine patient‐described experiences of endometriosis diagnosis.DesignMixed‐methods study.SettingOnline patient‐led endometriosis support groups.Population or SamplePeople with endometriosis aged over 18.MethodsA survey with qualitative and quantitative questions was distributed through online patient‐led endometriosis support groups. Descriptive statistics were used to analyse quantitative data, and thematic analysis was used for qualitative responses. Quantitative and qualitative data were triangulated to examine patient experiences of endometriosis diagnosis across age groups.Main outcome measuresExperiences of endometriosis diagnosis among people with endometriosis.ResultsA total of 2017 people with endometriosis from 63 countries responded to the questionnaire. Patients experienced an average delay of 3.7 years between symptom onset and first presentation of symptoms to a physician (the care‐seeking delay) and an average delay of 5.8 years between first presentation of symptoms to a physician and diagnosis of endometriosis (the healthcare‐related delay). Patients experienced an average total diagnostic delay of 9.6 years. Participants aged over 35 at the time of the study reported significantly longer times to receive an endometriosis diagnosis (mean 10.7, 95% confidence interval [CI] 10.2–11.2) compared with participants age 18–24 (6.8, 95% CI 6.1–7.5 years). The qualitative analysis identified the following themes: physicians normalised endometriosis symptoms, patients felt their symptoms were ignored by physicians because they were considered unreliable, and participant character attributes (e.g. age, appearance, weight or physical ability) led to clinician dismissal.ConclusionsPeople with endometriosis of all age groups reported pervasive negative healthcare experiences during their adolescence. Patients experience delays in seeking care and in receiving a diagnosis once presenting for care.

show abstract

Increased overall morbidity in women with endometriosis: a population-based follow-up study until age 50

Cited by 8 publications

References 39 publications

Development and Validation of a novelin vitrodiagnostic test for endometriosis

Development and Validation of a novelin vitrodiagnostic test for endometriosis

Development and Validation of an Endometriosis Diagnostic Method Based on Serum Biomarkers and Clinical Variables

Patient experiences of endometriosis diagnosis: A mixed methods approach

Contact Info

Product

Resources

About